Nektar Therapeutics Securities Fraud Lawsuit
Analysis based on 91 articles · First reported Apr 02, 2026 · Last updated Apr 27, 2026
The class action lawsuit against Nektar Therapeutics, alleging securities fraud due to misleading statements about its REZOLVE-AA trial, has caused a significant drop in Nektar Therapeutics' stock price. This event highlights the risks associated with biopharmaceutical companies' clinical trial disclosures and can lead to increased scrutiny from investors and regulatory bodies in the biotechnology industry.
A class action lawsuit has been filed against Nektar Therapeutics and certain officers in the United States — United States District Court for the Northern District of California. The lawsuit, initiated by Pomerantz LLP, Rosen Law Firm, and The Schall Law Firm, alleges that Nektar Therapeutics made materially false and misleading statements regarding its Phase 2b REZOLVE-AA trial for rezpegaldesleukin, a treatment for alopecia areata. Specifically, the complaint claims that enrollment in the trial did not follow applicable instructions and protocol standards, which negatively impacted the trial's results and overstated its overall integrity. When Nektar Therapeutics announced on December 16, 2025, that the trial failed to reach statistical significance, attributing it to ineligible patient inclusion, its stock price fell by 7.77%. The class period for affected investors is between February 26, 2025, and December 15, 2025, with a lead plaintiff deadline of May 5, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard